Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2007

01.10.2007 | Epidemiology

Psychometric properties of the simplified Chinese version of the EORTC QLQ-BR53 for measuring quality of life for breast cancer patients

verfasst von: Chonghua Wan, Xueliang Tang, Xin M. Tu, Changyong Feng, Susan Messing, Qiong Meng, Xiaoqing Zhang

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

A Simplified Chinese version of the EORTC QLQ-BR53 was evaluated using responses from 233 patients with breast cancer in China by assessing the construct and criterion-related validity, internal consistency and test–retest reliability, and responsiveness as measured by score changes of the scales. Internal consistency reliability measured by Cronbach’s coefficient α is greater than 0.75 for most multi-item scales except cognitive functioning (0.41) and breast symptoms (0.71). Test–retest reliability coefficients for all domains are greater than 0.80 with the exception of physical functioning (0.65), social functioning (0.75), appetite loss (0.75), diarrhea (0.72), and body image (0.72). Correlation and factor analysis among domains and items showed good construct validity for both QLQ-C30 and QLQ-BR23. Score changes over time were observed in most domains except emotional functioning, global health status/QOL, dyspnoea, constipation, diarrhea, financial difficulties, sexual functioning, sexual enjoyment, and breast symptoms. Therefore, the Simplified Chinese version of QLQ-BR53 shows reasonable validity, reliability, and responsiveness and can be used to measure QOL for Chinese patients with breast cancer.
Literatur
1.
Zurück zum Zitat Society AC (2000). Cancer facts and figures-2000. Atlanta Society AC (2000). Cancer facts and figures-2000. Atlanta
2.
Zurück zum Zitat Coebergh JWW, Janssen-Heijnen MLG, Louwman WJ et al (2001) Cancer incidence and survival in the South of the Netherlands,1955–1999 and incidence in the North of Belgium, 1996–1998. Comprehensive Cancer Centre South (IKZ), Eindhoven Coebergh JWW, Janssen-Heijnen MLG, Louwman WJ et al (2001) Cancer incidence and survival in the South of the Netherlands,1955–1999 and incidence in the North of Belgium, 1996–1998. Comprehensive Cancer Centre South (IKZ), Eindhoven
3.
Zurück zum Zitat Selby PJ, Champon JA, Etazadi-Amoli J et al (1984) The development of a method for assessing the quality of life of cancer patients. Br J Cancer 50(1):13–22PubMed Selby PJ, Champon JA, Etazadi-Amoli J et al (1984) The development of a method for assessing the quality of life of cancer patients. Br J Cancer 50(1):13–22PubMed
4.
Zurück zum Zitat Brade MJ, Cella DF, Mo F et al (1997) Reliability and validity of the functional assessment of cancer therapy-Breast quality-of- life instrument. J Clin Oncol 15(3):974–986 Brade MJ, Cella DF, Mo F et al (1997) Reliability and validity of the functional assessment of cancer therapy-Breast quality-of- life instrument. J Clin Oncol 15(3):974–986
5.
Zurück zum Zitat Cella DF, Tulsky DS, Gray G et al (1993) The functional assessment of cancer therapy scale development and validation of the general measure. J Clin Oncol 11(3):570–579PubMed Cella DF, Tulsky DS, Gray G et al (1993) The functional assessment of cancer therapy scale development and validation of the general measure. J Clin Oncol 11(3):570–579PubMed
6.
Zurück zum Zitat Aaronson NK, Cull A, Kaasa S et al (1994) The European Organization for Research and Treatment of Cancer (EORTC) modular approach to quality of life assessment in oncology. Int J Ment Health 23(2):75–96 Aaronson NK, Cull A, Kaasa S et al (1994) The European Organization for Research and Treatment of Cancer (EORTC) modular approach to quality of life assessment in oncology. Int J Ment Health 23(2):75–96
7.
Zurück zum Zitat Sprangers MA (1996) The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 14(10):2756–2768PubMed Sprangers MA (1996) The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 14(10):2756–2768PubMed
8.
Zurück zum Zitat Van der Steeg AFW, De Vries J, Roukema JA (2004) Quality of life and health status in breast carcinoma. EJSO 30:1051–1057PubMedCrossRef Van der Steeg AFW, De Vries J, Roukema JA (2004) Quality of life and health status in breast carcinoma. EJSO 30:1051–1057PubMedCrossRef
9.
Zurück zum Zitat Kim S, Hays RD, Birbeck GL et al (2003) Responsiveness of the Quality of Life in Epilepsy Inventory (QOLIE-89) in an Antiepileptic Drug Trial. Qual Life Res 12(2):147–155PubMedCrossRef Kim S, Hays RD, Birbeck GL et al (2003) Responsiveness of the Quality of Life in Epilepsy Inventory (QOLIE-89) in an Antiepileptic Drug Trial. Qual Life Res 12(2):147–155PubMedCrossRef
10.
Zurück zum Zitat Kosinski M, Bjorner JB, Ware Jr JE et al (2003) The Responsiveness of Headache Impact Scales Scored Using ‘Classical’ and ‘Modern’ Psychometric Methods: A Re-analysis of Three Clinical Trials. Qual Life Res 12(8):903–912PubMedCrossRef Kosinski M, Bjorner JB, Ware Jr JE et al (2003) The Responsiveness of Headache Impact Scales Scored Using ‘Classical’ and ‘Modern’ Psychometric Methods: A Re-analysis of Three Clinical Trials. Qual Life Res 12(8):903–912PubMedCrossRef
11.
Zurück zum Zitat Yun YH, Bae SH, Kang IO et al (2004) Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer (EORTC) Breast-Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR23). Support Care Cancer 12(6):441–445PubMedCrossRef Yun YH, Bae SH, Kang IO et al (2004) Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer (EORTC) Breast-Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR23). Support Care Cancer 12(6):441–445PubMedCrossRef
12.
Zurück zum Zitat Chie WC, Chang KJ, Huang CS, Kuo WH (2003) Quality of life of breast cancer patients in Taiwan: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-BR23. Psychooncology 12(7):729–735PubMedCrossRef Chie WC, Chang KJ, Huang CS, Kuo WH (2003) Quality of life of breast cancer patients in Taiwan: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-BR23. Psychooncology 12(7):729–735PubMedCrossRef
13.
Zurück zum Zitat Montazeri A, Harirchi I, Vahdani M et al (2000) The EORTC breast cancer-specific quality of life questionnaire (EORTC QLQ-BR23): translation and validation study of the Iranian version. Qual Life Res 9(2):177–184PubMedCrossRef Montazeri A, Harirchi I, Vahdani M et al (2000) The EORTC breast cancer-specific quality of life questionnaire (EORTC QLQ-BR23): translation and validation study of the Iranian version. Qual Life Res 9(2):177–184PubMedCrossRef
Metadaten
Titel
Psychometric properties of the simplified Chinese version of the EORTC QLQ-BR53 for measuring quality of life for breast cancer patients
verfasst von
Chonghua Wan
Xueliang Tang
Xin M. Tu
Changyong Feng
Susan Messing
Qiong Meng
Xiaoqing Zhang
Publikationsdatum
01.10.2007
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2007
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9443-1

Weitere Artikel der Ausgabe 2/2007

Breast Cancer Research and Treatment 2/2007 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.